Metastases in bones, lymph nodes and lungs are common challenges among oncology patients (e.g. breast cancer, prostate cancer, osteosarcoma) and are the primary cause of death. Efficacious new treatment options are sorely needed. Alpha-particle emitting radionuclides being highly cytotoxic may fulfil this critical need. We study a novel technology with potentially broad therapeutic applications for cancer micrometastases by means of dual targeted alpha particle radiation. The treatment involves administration of a bone-seeking, alpha-particle emitting radionuclide 224Ra and its daughter radionuclide 212Pb solution containing chelator-labelled new and existing molecular ligands and tumour-associated monoclonal antibodies (mAb) as carriers for the daughter radionuclide. Pb-212 is a source of highly cytotoxic alpha particles via its decay to 212Bi daughter.
Contact information Asta Juzeniene, Scientist, Ph.D. Department of Radiation Biology, Institute for Cancer Research The Norwegian Radium Hospital, Montebello, N-0310 Oslo, Norway Tel. +47 22 78 12 00, Fax +47 22 78 12 07
Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH(2020) In situ Generated 212Pb-PSMA Ligand in a 224Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells Curr Radiopharm(in press) DOI 10.2174/1874471013666200511000532, PubMed 32389119
Grigalavicius M, Mastrangelopoulou M, Arous D, Juzeniene A, Ménard M, Skarpen E, Berg K, Theodossiou TA(2020) Photodynamic Efficacy of Cercosporin in 3D Tumor Cell Cultures Photochem Photobiol, 96(3), 699-707 DOI 10.1111/php.13257, PubMed 32125700
Berge LAM, Andreassen BK, Stenehjem JS, Heir T, Furu K, Juzeniene A, Roscher I, Larsen IK, Green AC, Veierød MB, Robsahm TE(2020) Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study Clin Epidemiol, 12, 193-202 DOI 10.2147/CLEP.S241249, PubMed 32110111